Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Biliary Tract Cancer
Спонсор: AstraZeneca AB
Налично на:
БГ
Обобщение
Trial status: Authorised
Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Overall survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Описание
Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 232 participants
Интервенции
GEMCITABINE
Drug
IMFINZI 50 mg/mL concentrate for solution for infusion
БГ
EN